Ernexa Therapeutics Inc. Warrants (ERNAW)
Stock · NASDAQ · Health Care
$0.0253as of 10/14/2026
Price chart
Active signals
Resistance level
$0.04962
Industry
Biotechnology: Pharmaceutical Preparations
About ERNAW
Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of treatment of cancer and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-201, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rhe…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 5
Fundamentals
- 1-day range
- Market cap
- $52.4K
- P/E (trailing)
- —
- P/E (forward)
- —
- EPS (trailing)
- —
- Dividend yield
- —
- Beta
- —
- Avg. volume
- —
52-week range
$0.0213$0.2278
Ernexa Therapeutics Inc. Warrants Competitors
Chosen by industry and closest market cap.
- ERNAWErnexa Therapeutics Inc. Warrants$0.0253▼ 9.96%Market cap $52.4KP/E —$0.0213$0.2278
- CDTTWCDT Equity Inc. Warrant$0.0074▲ 21.31%Market cap $9.3KP/E —$0.002$0.02
- CINGWCingulate Inc. Warrants$0.01▲ 14.94%Market cap $133.3KP/E —$0.0026$0.12
- BFRIWBiofrontera Inc. Warrants$0.0052▼ 7.14%Market cap $357.2KP/E —$0.0052$0.1484
- BIVIWBioVie Inc. Warrant$0.2301▼ 7.96%Market cap $1.06MP/E —$0.13$0.79
- BDRXBiodexa Pharmaceuticals plc American Depositary Shs$0.456▲ 5.80%Market cap $1.10MP/E —$0.3371$44.7
- MTNBMatinas Biopharma Holdings Inc. Common Stock$2.37▼ 2.07%Market cap $1.72MP/E —$2.26$28.95
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| ERNAW Ernexa Therapeutics Inc. Warrants | $52.4K | — | $0.0253 | ▼ 9.96% | $0.0213$0.2278 |
| CDTTW CDT Equity Inc. Warrant | $9.3K | — | $0.0074 | ▲ 21.31% | $0.002$0.02 |
| CINGW Cingulate Inc. Warrants | $133.3K | — | $0.01 | ▲ 14.94% | $0.0026$0.12 |
| BFRIW Biofrontera Inc. Warrants | $357.2K | — | $0.0052 | ▼ 7.14% | $0.0052$0.1484 |
| BIVIW BioVie Inc. Warrant | $1.06M | — | $0.2301 | ▼ 7.96% | $0.13$0.79 |
| BDRX Biodexa Pharmaceuticals plc American Depositary Shs | $1.10M | — | $0.456 | ▲ 5.80% | $0.3371$44.7 |
| MTNB Matinas Biopharma Holdings Inc. Common Stock | $1.72M | — | $2.37 | ▼ 2.07% | $2.26$28.95 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Ernexa Therapeutics’ ERNA-101 Selected for Flash Talk Presentation at Nature Conferences’ Next-Generation Cancer Therapeutics Meeting Co-Hosted by MD Anderson Cancer CenterYahoo · 10/6/2026
- Ernexa Therapeutics CEO Corner Highlights Appointment of Dr. Robert J. Spiegel as Company Sharpens Oncology Focus and Advances ERNA-101 Toward the ClinicYahoo · 10/1/2026
- Ernexa Therapeutics Reports Compelling ERNA-101 Safety Results Across Three Critical IND-Enabling Studies, Advancing Toward Planned Q4 2026 INDYahoo · 9/30/2026
- Ernexa Therapeutics Selected for Emerging Track at 2026 Cell & Gene Meeting on the Mesa, Highlighting ERNA-101 and Focused Oncology StrategyYahoo · 9/29/2026
- Ernexa Therapeutics Appoints Accomplished Biopharmaceutical Executive Robert J. Spiegel, M.D., FACP, to Board of DirectorsYahoo · 9/17/2026
- Ernexa Therapeutics Reports Positive Disease Modifying ERNA-201 Preclinical Data, Reinforcing iMSC Platform as Company Accelerates Oncology Strategy and ERNA-101 Toward First-in-Human DosingYahoo · 9/15/2026
- Ernexa Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment ConferenceYahoo · 9/14/2026
Institutional Ownership
March 31, 2026
- Total shares held
- 6.80M
- Total value held
- $195.3K
- Institutional holders
- 5
Top holders this quarter
- Unknown4.00M
- Unknown2.00M
- Unknown400.0K
- Unknown253.8K
- Unknown149.3K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 3, 2026
Ernexa Warrants: ERNA-101 Safety Data and New CEO
Ernexa Therapeutics announced that its ERNA-101 drug showed positive safety results in three key studies, supporting a planned IND filing in late 2026. The company also appointed Dr. Robert J. Spiegel as CEO to sharpen its oncology focus. These developments are relevant to the warrants as they indicate progress in the company's primary development pipeline.
Ernexa Warrants: ERNA-101 Safety Data and New CEO. Ernexa Therapeutics announced that its ERNA-101 drug showed positive safety results in three key studies, supporting a planned IND filing in late 2026. The company also appointed Dr. Robert J. Spiegel as CEO to sharpen its oncology focus. These developments are relevant to the warrants as they indicate progress in the company's primary development pipeline.